Healthcare / Medical Instruments & SuppliesTokyo
$1715.00
-71.00 (-3.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 22%
FCF escenarios
weak_data · normalized FCF $128.0M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10.1B
P/E
111.7x
↑EV/EBITDA
22.9x
↑ROE
7.4%
↑Gross Margin
62.3%
↑Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-4.0%
FCF / Net income
-0.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.01B · net income $199.6M · FCF $-79.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.01B | $2.01B | $1.91B | $1.15B | — |
| Net Income | $199.6M | $199.6M | $238.2M | $-32.1M | — |
| EBITDA | $437.2M | $437.2M | $510.6M | $107.5M | — |
| EPS | 33.96 | 33.96 | 40.58 | -5.48 | — |
| Gross Margin | 62.3% | 62.3% | 61.0% | 60.8% | — |
| Operating Margin | 14.2% | 14.2% | 16.1% | -6.2% | — |
| Net Margin | 9.9% | 9.9% | 12.5% | -2.8% | — |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.24 | 0.30 | 0.42 |
| Current Ratio | 6.44 | 6.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-79.7M | $-79.7M | $128.0M | $171.2M | — |
| Returns | |||||
| ROE | 7.4% | 7.4% | 9.6% | -1.4% | — |
| Valuation | |||||
| P/E | 111.65 | 111.65 | 55.17 | — | — |
| EV/EBITDA | 22.85 | 22.85 | 25.37 | 118.59 | — |
| P/B | 3.74 | 3.74 | 5.30 | 5.75 | 8.78 |
| Growth & Yield | |||||
| Revenue Growth | 5.3% | 5.3% | 65.8% | — | — |
| EPS Growth | -16.3% | -16.3% | 840.5% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
64.9%
EPS terminal req.
$152.18
Spread vs growth
-81.2%
5Y implied EPS CAGR
40.2%
EPS terminal req.
$184.13
Spread vs growth
-56.5%
10Y implied EPS CAGR
24.2%
EPS terminal req.
$296.55
Spread vs growth
-40.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+40.6%
Start / end P/E
30.1x → 50.5x
EPS bridge
40.58 → 33.96
Residual
-11.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.